IDH2 and central nervous system cancer: The diagnostic test algorithm of IDH‐mutant gliomas has been streamlined in a recent consensus publication cIMPACt‐NOW update 5 [9], recommending that 1p/19q testing is not required in IDH‐mutant astrocytic tumours with loss of nuclear ATRX expression.